Global Genome Engineering Editing Market Growth (Status and Outlook) 2025-2031

The global Genome Engineering Editing market size is predicted to grow from US$ 8182 million in 2025 to US$ 23420 million in 2031; it is expected to grow at a CAGR of 19.2% from 2025 to 2031.

Genome Engineering Editing is a modern molecular biology technology that involves targeted modifications to the genome of an organism to change the sequence of a target gene or regulate its expression. This technology is largely based on genome editing tools such as CRISPR-Cas9, which allows scientists to precisely add, delete or replace an organism's genes.

Global key players of Genome Engineering Editing include Thermo Fisher Scientific, AstraZeneca, SIGMA ALDRICH, Agilent Technologies, Illumina, etc. The top five players hold a share over 52%. North America is the largest market, and has a share about 37%, followed by Asia-Pacific and Europe with share 25% and 18%, separately. In terms of product type, CRISPR RNP is the largest segment, occupied for a share of 39%. In terms of application, GMP has a share about 70 percent.

LPI (LP Information)' newest research report, the “Genome Engineering Editing Industry Forecast” looks at past sales and reviews total world Genome Engineering Editing sales in 2024, providing a comprehensive analysis by region and market sector of projected Genome Engineering Editing sales for 2025 through 2031. With Genome Engineering Editing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genome Engineering Editing industry.

This Insight Report provides a comprehensive analysis of the global Genome Engineering Editing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Genome Engineering Editing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genome Engineering Editing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genome Engineering Editing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genome Engineering Editing.

This report presents a comprehensive overview, market shares, and growth opportunities of Genome Engineering Editing market by product type, application, key players and key regions and countries.

Segmentation by Type:

CRISPR RNP

CRISPR mRNA

CRISPR Virus Delivery

Others

Segmentation by Application:

RUO

GMP

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Thermo Fisher Scientific

SIGMA ALDRICH

Dharmacon（Horizo​​n Discovery）

Cellectics

CRISPR Therapeutics

AstraZeneca

Bio Rad

Allele Biotech

Recombinetics

Lonza

Illumina

Editas Medicine

Agilent Technologies

QIAGEN NV

Please note: The report will take approximately 2 business days to prepare and deliver.